Induction chemotherapy in the management of head and neck cancer

Authors

  • Matthew G. Fury MD, PhD,

    1. Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    2. Department of Medicine, Weill Medical College of Cornell University, New York, New York
    Search for more papers by this author
    • Assistant Attending Physician. Memorial Sloan-Kettering Cancer Center.

    • Instructor, Weill Medical College of Cornell University.

  • Jatin P. Shah MD, PhD(Hon), FACS, FRCS(Hon), FDSRCS(Hon), FRACS(Hon)

    Corresponding author
    1. Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    2. Department of Surgery, Weill Medical College of Cornell University, New York, New York
    • Chief, Head and Neck Service, Memorial Sloan-Kettering Cancer Center; 1275 York Avenue, New York, NY 10065. Fax: 212-717-3302.
    Search for more papers by this author
    • Chief, Head and Neck Service, Memorial Sloan-Kettering Cancer Center.

    • Professor, Weill Medical College of Cornell University.


Abstract

The strategy of induction chemotherapy prior to planned definitive local therapy for head and neck squamous cell carcinoma has been studied for over 30 years, and appears to have a role in select clinical situations. Here we review landmark studies regarding induction chemotherapy, both in the pre-taxane era and in the current taxane era, and we address some of the unresolved questions regarding the role of induction chemotherapy in head and neck cancer. J. Surg. Oncol. 2010; 101:292–298. © 2010 Wiley-Liss, Inc.

Ancillary